Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief ReportXiuning Le, Helena A. Yu, Zofia Piotrowska et al.|Journal of Thoracic Oncology|2025Cited by 5
329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinibJonathan W. Riess, H.A. Yu, J.A. De Langen et al.|Annals of Oncology|2022Cited by 4